Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NuCana Announces Update for Phase 3 Biliary Tract Cancer Study
Details : NUC-3373 (fosifloxuridine nafalbenamide), a new chemical entity derived from the nucleoside analog 5-fluorouracil, continues rapid development with multiple data readouts and dosing of first patients in Phase 3 colorectal cancer study.
Brand Name : NUC-3373
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 02, 2022
Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : 10 patient out of 37 case studies highlighted NUC-3373’s ability to stabilize disease and achieve prolonged durations of progression-free survival. Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of...
Brand Name : NUC-3373
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 15, 2021
Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?